Literature DB >> 17157602

Recurrent bullous retinal detachments from photodynamic therapy for idiopathic polypoidal choroidal vasculopathy.

Manvi Prakash1, Dennis P Han.   

Abstract

PURPOSE: To report the recurrent bullous retinal detachments as complications of photodynamic therapy (PDT) for idiopathic polypoidal choroidal vasculopathy (IPCV).
DESIGN: Interventional case report.
METHODS: A pseudophakic 84-year-old-woman had IPCV and decreased vision. Angiography demonstrated macular leakage. PDT with verteporfin was applied. Two days later, visual acuity decreased from 20/50 to 20/400. Examination revealed extensive inferior subretinal fluid, which mimicked a pseudophakic rhegmatogenous retinal detachment. A scleral buckle was placed; no retinal breaks were identified.
RESULTS: Vision and fluid resolved over three weeks. Four months later, examination revealed decreased vision and persistent leakage. Two days after repeat PDT, bullous exudative macular detachment recurred. Detachment resolved over two weeks; visual acuity returned to 20/50.
CONCLUSION: IPCV that is treated with PDT may be complicated by iatrogenic bullous exudative retinal detachments that resemble rhegmatogenous detachments. Modified treatment parameters may reduce the risk of recurrence. The natural history likely includes spontaneous resolution and visual recovery.

Entities:  

Mesh:

Year:  2006        PMID: 17157602     DOI: 10.1016/j.ajo.2006.06.059

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Transient serous retinal detachment after photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Hideaki Tobita; Kyoko Ohno-Matsui; Manabu Ogawa; Yuh Kaneko; Noriaki Shimada; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

2.  Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Zeon Lee; Miho Haruyama; Eriko Akaza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.